focus -WSS

focus

author：comprehensive 2025-09-28 07:29:22 Page View：42

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： HIV vaccine remains elusive. Immunologists keep trying new ideas
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Statins reduce cardiovascular risk in people living with HIV

AstatinadayreducestheriskofheartdiseaseinyoungerpeoplelivingwithHIV,accordingtoanewstudypublishedSun

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Severe heat forecast: Where scorching temperatures will persist over the next week

4:01Amanwalksalongasidewalkunderthemisters,July14,2023,indowntownPhoenix.MattYork/APAnunrelentinghea